Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
Status:
RECRUITING
Trial end date:
2029-04-30
Target enrollment:
Participant gender:
Summary
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received platinum-based first-line chemotherapy. Participants will receive tarlatamab on Cycle 1 Day 1 (C1D1), Day 8 (C1D8), and Day 15 (C1D15), followed by administration every two weeks thereafter. No placebo control is included in this study.
Phase:
PHASE2
Details
Lead Sponsor:
Inkeun Park
Collaborators:
Samsung Medical Center Seoul National University Hospital Severance Hospital